Novo Nordisk A/S: New Data Shows That Type 2 Diabetes Patients Who Start Insulin Therapy with Once-Daily NovoMix(R) 30 Achieve Significantly Greater HbA1c Reduction Than with Insulin Glargine

VIENNA--(BUSINESS WIRE)--Data from a new study presented today at the annual meeting of the European Association for the Study of Diabetes (EASD) shows that type 2 diabetes patients starting insulin treatment with once-daily injection of NovoMix® 30 (biphasic insulin aspart) achieve a significantly greater HbA1c reduction compared to patients starting with a daily injection of insulin glargine. Treatment with NovoMix® 30 also resulted in significantly lower blood glucose levels after dinner and at bedtime, as compared to insulin glargine.